Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christina Appenzeller

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Blood|March 30, 2023
A spiky issueTobias Silzle, Christina Appenzeller
Case Reports in Oncology|September 26, 2022
Sotorasib Shows Intracranial Activity in Patients with <i>KRAS G12C-</i>Mutated Adenocarcinoma of the Lung and Untreated Active Brain MetastasesKira-Lee Koster, Christina Appenzeller, Arno Lauber, et al.
Swiss Medical Weekly|November 8, 2002
Serum C-reactive protein in children with adenovirus infectionChristina Appenzeller, Roland A Ammann, Andrea Duppenthaler, et al.
Pneumonia (Nathan Qld.)|January 25, 2021
HSV-pneumonitis in a patient with lung cancer receiving check point inhibitors - a case reportJohannes Sumer, Frederike Waldeck, Nadja Fischer, et al.
Haematologica|June 13, 2015
The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cellsMarianne Kraus, Juergen Bader, Paul P Geurink, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2021
Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU StudyMelissa L Johnson, Zanete Zvirbule, Konstantin Laktionov, et al.
Oncoimmunology|December 3, 2021
Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survivalFiamma Berner, Rebekka Niederer, Jolien J Luimstra, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Blood|March 30, 2023
A spiky issueTobias Silzle, Christina Appenzeller
Case Reports in Oncology|September 26, 2022
Sotorasib Shows Intracranial Activity in Patients with <i>KRAS G12C-</i>Mutated Adenocarcinoma of the Lung and Untreated Active Brain MetastasesKira-Lee Koster, Christina Appenzeller, Arno Lauber, et al.
Swiss Medical Weekly|November 8, 2002
Serum C-reactive protein in children with adenovirus infectionChristina Appenzeller, Roland A Ammann, Andrea Duppenthaler, et al.
Pneumonia (Nathan Qld.)|January 25, 2021
HSV-pneumonitis in a patient with lung cancer receiving check point inhibitors - a case reportJohannes Sumer, Frederike Waldeck, Nadja Fischer, et al.
Haematologica|June 13, 2015
The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cellsMarianne Kraus, Juergen Bader, Paul P Geurink, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2021
Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU StudyMelissa L Johnson, Zanete Zvirbule, Konstantin Laktionov, et al.
Oncoimmunology|December 3, 2021
Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survivalFiamma Berner, Rebekka Niederer, Jolien J Luimstra, et al.
Pageof 1